Sanofi (France)
NEWS
Last week was an unusually busy week for clinical trial news, with numerous companies presenting results at conferences. Here’s a look at the top stories.
The deal had the upside potential of $1.7 billion but showed mixed results in three Phase III clinical trials. Sanofi announced it had terminated the collaboration, but Lexicon lashed out, alleging Sanofi’s termination was “invalid” and the company was “in breach of contract.”
Glioblastoma is very difficult to treat and there have been several recent clinical trial failures for new drugs.
The two companies will seek approval for the biologic as a treatment for severe atopic dermatitis in children ages six to 11.
There were a number of major companies reporting their second-quarter financials for the year. Here’s a look at five of the bigger announcements this week.
Sanofi reported overall net sales increased by 5.5% for the second quarter, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.
Sanofi will be responsible for leading the clinical program and funding all studies needed to support the over-the-counter switch in the United States and will also be responsible for the regulatory submissions.
The introduction of EHLs allowed hemophilia patients to live a life beyond their disease, with improved quality of life, the study showed.
Clinical data showed Dupixent reduces nasal polyp size, improves congestion and loss of smell, while reducing the need for surgery and systemic corticosteroids.
JOBS
IN THE PRESS